65,437 trials
Multiple Sclerosis
Primary: Gadolinium-enhancing (Gd+)Lesion Number Change. — 4.0 Gd+ lesions
Partial Edentulism · Tooth Disease
Primary: Crestal Bone Regression (Amount of Bone Measured) Around Each Implant Unit — -0.7440; -0.8445 millimeters
Influenza
Primary: Geometric Mean Titers (GMTs) of Haemagglutination Inhibition (HI) Antibodies Against Fluviral Vaccine Strains. — 39.2; 15.2; 14.1; 13.0 Titer
Overactive Bladder · Neurogenic Detrusor Overactivity
Primary: Absorption Rate Constant (Ka) — 0.44 1/hour (hr)
Atopic Dermatitis
Primary: Change in Pruritis Visual Analog Scale (VAS) — -12.4; -15.5; -13.9; -6.2 mm
Persistent Allergic Asthma
Primary: Change From Baseline in Asthma Control Test (ACT) After 24 Weeks of Treatment — 5.2; 4.7 Score on a scale
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Malignant Melanoma
Primary: Overall Survival — 43; 75; 293; 261 participants — p=<0.0001
Osteoporosis · Postmenopausal
Primary: Change in Bone Mineral Density (BMD) From Baseline to Month 36 — -0.11; 0.03 Percent
Male Osteoporosis
Primary: Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 24 Months — 1.6; 4.9 Percentage of Participants
Breast Cancer
Primary: Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST) — 6.02; 6.05; 6.58; 7.10 Months — p=0.6686
Cataract
Primary: Best Corrected Distance Visual Acuity — 119; 120 participants
Osteoporosis, Postmenopausal
Primary: Percent Change From Baseline in Surface-to-Curve Ratio (SCR) in the Distal Radius at Month 18 Endpoint — 4.53 percent (%) change of ratio — p=0.363
Healthy
Primary: Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population — 124; 62; 1333; 215 titer
Hypertension · Hypercholesterolemia
Primary: Framingham 10-year Risk of Total Coronary Heart Disease (CHD) at Month 12 — 12.5; 16.3 percent risk — p=<0.001